Orvosi Hetilap
Volume/Issue:
Volume 153: Issue 26
The long-term treatment of schizophrenia
Author: Róbert Herold 1
View More View Less
  • 1 Pécsi Tudományegyetem, Általános Orvostudományi Kar Pszichiátriai és Pszichoterápiás Klinika Pécs Rét u. 2. 7623
DOI:
https://doi.org/10.1556/oh.2012.29416
Page Count:
1007–1012
Publication Date:
01 Jul 2012
Online Publication Date:
26 Jun 2012
Article Category:
Research Article
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00
Purchase Online Subscription

  • Purchase article

    USD  $25.00

  • 1 year subscription (Individual Only)

    USD  $1,070.00

A szkizofrénia hosszú távú kezelése a legnagyobb kihívást jelentő feladatok közé tartozik a gyakorló orvosok számára. A legkifejezettebb nehézséget a betegek hiányos betegségbelátásából fakadó együttműködési problémák jelentik, ezért a szkizofrénia kezelése multimodális megközelítést igényel, ami a gyógyszeres kezelés mellett mindig magába foglalja a pszichoszociális intervenciókat is. A gyógyszeres kezelése fókuszában az antipszichotikus terápia áll, amelyen belül az utóbbi időben egyre nagyobb szerephez jutnak a második generációs szerek hosszú hatású injekciós formái. Megfelelően szervezett kezelési stratégiával a szkizofrénia kimenetele jelentősen módosítható, ami az életminőség és a szociális funkcionalitás javulásával jár együtt. Az időben elkezdett hatásos gyógyszereléssel és hatékony rehabilitációs beavatkozással a betegek számára reálisan elérhető cél a tartós remisszió. Orv. Hetil., 2012, 153, 1007–1012.

  • Tandon, R., Nasrallah, H. A., Keshavan, M. S.: Schizophrenia, “just the facts” 5. Treatment and prevention. Past, present, and future. Schizophr. Res., 2010, 122, 1–23.

    Keshavan M. S. , 'Schizophrenia, “just the facts” 5. Treatment and prevention. Past, present, and future ' (2010 ) 122 Schizophr. Res. : 1 -23.

    • Search Google Scholar

  • Potkin, S., Preda, A., Kalali, A., et al.: Challenges and solutions in developing new medications for Schizophrenia. J. Clin. Psychiatry, 2010, 71, 1391–1399.

    Kalali A. , 'Challenges and solutions in developing new medications for Schizophrenia ' (2010 ) 71 J. Clin. Psychiatry : 1391 -1399.

    • Search Google Scholar

  • Robinson, D. G., Woerner, M. G., McMeniman, M., et al.: Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am. J. Psychiatry, 2004, 161, 473–479.

    McMeniman M. , 'Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder ' (2004 ) 161 Am. J. Psychiatry : 473 -479.

    • Search Google Scholar

  • Tyrer, P., Kendall, T.: The spurious advance of antipsychotic drug therapy. Lancet, 2009, 373, 4–5.

    Kendall T. , 'The spurious advance of antipsychotic drug therapy ' (2009 ) 373 Lancet : 4 -5.

  • Leucht, S., Corves, C., Arbter, D., et al.: Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet, 2009, 373, 31–41.

    Arbter D. , 'Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis ' (2009 ) 373 Lancet : 31 -41.

    • Search Google Scholar

  • Nasrallah, H. A.: The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr. Scand., 2007, 115, 260–267.

    Nasrallah H. A. , 'The case for long-acting antipsychotic agents in the post-CATIE era ' (2007 ) 115 Acta Psychiatr. Scand. : 260 -267.

    • Search Google Scholar

  • Llorca, P. M.: Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Res., 2008, 161, 235–247.

    Llorca P. M. , 'Partial compliance in schizophrenia and the impact on patient outcomes ' (2008 ) 161 Psychiatry Res. : 235 -247.

    • Search Google Scholar

  • Subotnik, K. L., Nuechterlein, K. H., Ventura, J., et al.: Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. Am. J. Psychiatry, 2011, 168, 286–292.

    Ventura J. , 'Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia ' (2011 ) 168 Am. J. Psychiatry : 286 -292.

    • Search Google Scholar

  • Robinson, D., Woerner, M. G., Alvir, J. M., et al.: Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch. Gen. Psychiatry, 1999, 56, 241–247.

    Alvir J. M. , 'Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder ' (1999 ) 56 Arch. Gen. Psychiatry : 241 -247.

    • Search Google Scholar

  • Tényi, T., Fekete, S.: The role of poor insight and anosognosia in compliance and efficacy of treatment in schizophrenia. [A betegségbelátás hiánya, az anozognózia szerepe a terápiás együttműködésben és a kezelés eredményességében szkizofrén betegeknél.] Psychiat. Hung., 2010, 25, 12–19. [Hungarian]

    Fekete S. , 'The role of poor insight and anosognosia in compliance and efficacy of treatment in schizophrenia. [A betegségbelátás hiánya, az anozognózia szerepe a terápiás együttműködésben és a kezelés eredményességében szkizofrén betegeknél.] ' (2010 ) 25 Psychiat. Hung. : 12 -19.

    • Search Google Scholar

  • Amador, X. F.: Poor insight in schizophrenia: Implications for diagnosis and treatment. Psychiat. Hung., 2010, 25, 5–7.

    Amador X. F. , 'Poor insight in schizophrenia: Implications for diagnosis and treatment ' (2010 ) 25 Psychiat. Hung. : 5 -7.

    • Search Google Scholar

  • Pilling, J., Tényi, T., Fehér, L.: KOMP: Communication approach to protmote adherence in schizophrenia treatment. [KOMP: Szkizofrén betegek terápiás együttműködését segítő kommunikációs módszer.] Psychiat. Hung., 2010, 25, 36–48. [Hungarian]

    Fehér L. , 'KOMP: Communication approach to protmote adherence in schizophrenia treatment. [KOMP: Szkizofrén betegek terápiás együttműködését segítő kommunikációs módszer.] ' (2010 ) 25 Psychiat. Hung. : 36 -48.

    • Search Google Scholar

  • Kane, J. M.: Treatment programme and long-term outcome in chronic schizophrenia. Acta Psychiatr. Scand. Suppl., 1990, 82 (S358), 151–157.

    Kane J. M. , 'Treatment programme and long-term outcome in chronic schizophrenia ' (1990 ) 82 Acta Psychiatr. Scand. Suppl. : 151 -157.

    • Search Google Scholar

  • Volavka, J., Cooper, T. B., Czobor, P., et al.: High-dose treatment with haloperidol: the effect of dose reduction. J. Clin. Psychopharmacol., 2000, 20, 252–256.

    Czobor P. , 'High-dose treatment with haloperidol: the effect of dose reduction ' (2000 ) 20 J. Clin. Psychopharmacol. : 252 -256.

    • Search Google Scholar

  • Kane, J. M., Garcia-Ribera, C.: Clinical guideline recommendations for antipsychotic long-acting injections. Br. J. Psychiatry Suppl., 2009, 195, S63–S67.

    Garcia-Ribera C. , 'Clinical guideline recommendations for antipsychotic long-acting injections ' (2009 ) 195 Br. J. Psychiatry Suppl. : S63 -S67.

    • Search Google Scholar

  • Patel, M. X., Nikolaou, V., David, A. S.: Psychiatrists’ attitudes to maintenance medication for patients with schizophrenia. Psychol. Med., 2003, 33, 83–89.

    David A. S. , 'Psychiatrists’ attitudes to maintenance medication for patients with schizophrenia ' (2003 ) 33 Psychol. Med. : 83 -89.

    • Search Google Scholar

  • Hovens, J., Roman, B., van Dinter, R.: Patients with schizophrenia prefer long-acting injections. Schizophr. Res., 2006, 81, A120.

    Dinter R. , 'Patients with schizophrenia prefer long-acting injections ' (2006 ) 81 Schizophr. Res. : A120 -.

    • Search Google Scholar

  • Caroli, F., Rajmondet, P., Izard, I., et al.: Opinions of French patients with schizophrenia regarding injectable medication. Patient Prefer. Adherence, 2011, 5, 165–171.

    Izard I. , 'Opinions of French patients with schizophrenia regarding injectable medication ' (2011 ) 5 Patient Prefer. Adherence : 165 -171.

    • Search Google Scholar

  • Citrome, L.: Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic. Int. J. Clin. Pract., 2009, 63, 140–150.

    Citrome L. , 'Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic ' (2009 ) 63 Int. J. Clin. Pract. : 140 -150.

    • Search Google Scholar

  • Citrome, L.: Paliperidone palmitate – review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. Int. J. Clin. Pract., 2010, 64, 216–239.

    Citrome L. , 'Paliperidone palmitate – review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication ' (2010 ) 64 Int. J. Clin. Pract. : 216 -239.

    • Search Google Scholar

  • Kane, J. M., Eerdekens, M., Lindenmayer, J. P., et al.: Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am. J. Psychiatry, 2003, 160, 1125–1132.

    Lindenmayer J. P. , 'Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic ' (2003 ) 160 Am. J. Psychiatry : 1125 -1132.

    • Search Google Scholar

  • Kahn, R. S., Fleischhacker, W. W., Boter, H., et al.: Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet, 2008, 371, 1085–1097.

    Boter H. , 'Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial ' (2008 ) 371 Lancet : 1085 -1097.

    • Search Google Scholar

  • Weiden, P. J., Schooler, N. R., Weedon, J. C., et al.: A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. J. Clin. Psychiatry, 2009, 70, 1397–1406.

    Weedon J. C. , 'A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome ' (2009 ) 70 J. Clin. Psychiatry : 1397 -1406.

    • Search Google Scholar

  • Emsley, R., Medori, R., Koen, L., et al.: Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J. Clin. Psychopharmacol., 2008, 28, 210–213.

    Koen L. , 'Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study ' (2008 ) 28 J. Clin. Psychopharmacol. : 210 -213.

    • Search Google Scholar

  • Olivares, J. M., Rodriguez-Morales, A., Diels, J., et al.: Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur. Psychiatry, 2009, 24, 287–296.

    Diels J. , 'Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR) ' (2009 ) 24 Eur. Psychiatry : 287 -296.

    • Search Google Scholar

  • Peuskens, J., Olivares, J., Pecenak, J., et al.: Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr. Med. Res. Opin., 2010, 26, 501–509.

    Pecenak J. , 'Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries ' (2010 ) 26 Curr. Med. Res. Opin. : 501 -509.

    • Search Google Scholar

  • Herold, R., Vanyó, P., Fehér, L.: The treatment with risperidone long-acting injectable significantly reduces the need for hospitalizations: The results from an one-year long, open, observational study. [A tartós hatású riszperidoninjekcióval végzett kezelés szignifikánsan csökkenti a kórházi kezelés igényét: Egyéves, nyílt, megfigyeléses vizsgálat eredményei.] Psychiat. Hung., 2010, 25, 20–35. [Hungarian]

    Fehér L. , 'The treatment with risperidone long-acting injectable significantly reduces the need for hospitalizations: The results from an one-year long, open, observational study. [A tartós hatású riszperidoninjekcióval végzett kezelés szignifikánsan csökkenti a kórházi kezelés igényét: Egyéves, nyílt, megfigyeléses vizsgálat eredményei.] ' (2010 ) 25 Psychiat. Hung. : 20 -35.

    • Search Google Scholar

  • Harangozó, J.: Evidence-based psychosocial interventions for community psychiatric care and rehabilitation. In: Psychotherapy of schizophrenia. (Bizonyítékokon alapuló pszichoszociális intervenciókkal történő közösségi pszichiátriai gondozás és rehabilitáció. In: A szkizofrénia pszichoterápiája.) Medicina Könyvkiadó, Budapest, 2006, 253–304. [Hungarian]

    Harangozó J. , '', in Psychotherapy of schizophrenia. (A szkizofrénia pszichoterápiája.) , (2006 ) -.

  • Nelson, G., Aubry, T., Lafrance, A.: A review of the literature on the effectiveness of housing and support, assertive community treatment, and intensive case management interventions for persons with mental illness who have been homeless. Am. J. Orthopsychiatry, 2007, 77, 350–361.

    Lafrance A. , 'A review of the literature on the effectiveness of housing and support, assertive community treatment, and intensive case management interventions for persons with mental illness who have been homeless ' (2007 ) 77 Am. J. Orthopsychiatry : 350 -361.

    • Search Google Scholar

  • Pilling, S., Bebbington P, Kuipers, E., et al.: Psychological treatments in schizophrenia: I. Meta-analysis of family intervention and cognitive behaviour therapy. Psychol. Med., 2002, 32, 763–782.

    Kuipers E. , 'Psychological treatments in schizophrenia: I. Meta-analysis of family intervention and cognitive behaviour therapy ' (2002 ) 32 Psychol. Med. : 763 -782.

    • Search Google Scholar

  • Turkington, D., Kingdon, D., Weiden, P. J.: Cognitive behavior therapy for schizophrenia. Am. J. Psychiatry, 2006, 163, 365–373.

    Weiden P. J. , 'Cognitive behavior therapy for schizophrenia ' (2006 ) 163 Am. J. Psychiatry : 365 -373.

    • Search Google Scholar

  • Wykes, T., Huddy, V., Cellard, C., et al.: A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am. J. Psychiatry, 2011, 168, 472–485.

    Cellard C. , 'A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes ' (2011 ) 168 Am. J. Psychiatry : 472 -485.

    • Search Google Scholar

  • Kurtz, M. M., Mueser, K. T.: A meta-analysis of controlled research on social skills training for schizophrenia. J. Consult. Clin. Psychol., 2008, 76, 491–504.

    Mueser K. T. , 'A meta-analysis of controlled research on social skills training for schizophrenia ' (2008 ) 76 J. Consult. Clin. Psychol. : 491 -504.

    • Search Google Scholar

  • Van Os, J., Kapur, S.: Schizophrenia. Lancet, 2009, 374, 635–645.

    Kapur S. , 'Schizophrenia ' (2009 ) 374 Lancet : 635 -645.
Cover Orvosi Hetilap
Orvosi Hetilap
Print ISSN:
0030-6002
Online ISSN:
1788-6120
Keywords:
szkizofrénia; hosszú távú kezelés; antipszichotikum; tartós hatású injekció; pszichoszociális kezelés; compliance; remisszió; schizophrenia; long-term treatment; antipsychotics; long-acting injection; psychosocial intervention; compliance; remission

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Aug 2020 8 0 0
Sep 2020 2 0 1
Oct 2020 5 0 0
Nov 2020 14 4 5
Dec 2020 35 0 0
Jan 2021 10 0 0
Feb 2021 0 0 0